{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.2","upperLimit":"49.4","value":"29.1"},{"groupId":"OG001","lowerLimit":"39.8","upperLimit":"67","value":"51.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"Percentage of patients who were progression free at 3 years. The 3-year progression free rate was estimated using the Kaplan Meier method.\n\nProgression is assessed when one of the following occur:\n\n* reappearance of monoclonal protein by immunofixation,\n* Increase in serum monoclonal paraprotein to \\>25% above the lowest response level,\n* Increase in urine M-protein to \\> 25% above the lowest remission value for 24-hour excretion.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive low-dose melphalan 20 mg/m\\^2 IV over 15-30 minutes on day 1 or 0.12 mg/kg tablet orally once daily on days 1-7 and dexamethasone 40 mg orally on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses. (Study treatment beyond one year is not allowed.)","id":"OG000","title":"Low-Dose Melphalan"},{"description":"Patients receive filgrastim (G-CSF) 10 mg/kg/day on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan 140 mg/m\\^2 IV for low risk or 200 mg/m\\^2 IV for high risk patients over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.","id":"OG001","title":"High-Dose Melphalan + Autologous HSC"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years","title":"3-Year Progression Free Survival","type":"POST_HOC","unitOfMeasure":"percentage of participants"}